Barclays Miami: Zealand Pharma CEO Adam Steensberg makes the case for last week's amylin data

He argues that investors are too focused on each percentage of weight loss and not focused enough on the tolerability of new options. He discusses the timeline for the phase 3 that will likely start later this year, and how it might look different than the phase 2 study that just read out.